Background: Pembrolizumab and nivolumab are immune checkpoint inhibitors targeting PD-1 that have recently been approved in pretreated recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients. In the clinic, some patients seem not only not to benefit from anti-PD-L1/PD-1 agents but rather to experience an acceleration of tumor growth kinetics (TGK).
Introduction
Every year, over 550 000 new cases of head and neck squamous cell carcinoma (HNSCC) and 300 000 related deaths are recorded worldwide [1] . Most HNSCC are locally advanced at the time of diagnosis. Despite a multimodal treatment, more than half of these patients will recur loco-regionally or distantly [2, 3] . Median overall survival (OS) in this patient population is less than a year [4] .
In vivo data have recently demonstrated the role played by the immune system to control and avoid tumor formation and progression. Mirroring this theory of immune surveillance, the immunoevasion concept has become a core hallmark of cancer [5] . PD-1 (programmed cell death protein 1) is a transmembrane immune checkpoint receptor that normally limits T cell effector functions within tissues. It is expressed on activated T cells, B cells, natural killer cells and some myeloid cells. Some tumor cells can upregulate the expression of PD-1 ligands (PD-L1 and PD-L2) and further block the antitumor immune response. PD-L1 was found to be expressed in 50%-60% of HNSCC [6] . PD-1/ PD-L1 inhibitors were reported to improve survival in several tumor types [7] [8] [9] .
In recurrent and/or metastatic (R/M) HNSCC patients, the pivotal phase III CheckMate 141 trial assessed the efficacy of nivolumab, an anti-PD-1 monoclonal antibody as compared to the investigator's choice [10] . The trial was stopped early due to a survival advantage for patients treated in the experimental arm with a statistically significant hazard ratio of 0.70. Pembrolizumab, another anti-PD-1 monoclonal antibody, was assessed in the KEYNOTE 012 trial in pretreated R/M HNSCC [11] . An overall response rate (ORR) of 18% was reported. Both molecules recently got FDA approval in this indication.
Due to their specific activity, the assessment of response to checkpoint inhibitors may be different from that of cytotoxics [12] . Pseudo-progressions, with an initial flare-up followed by tumor shrinkage, were reported in patients with metastatic melanoma [13] . Therefore, it has been advocated to continue immunotherapy after first disease progression provided that the general condition of the patient had improved [12] . Conversely, we have observed in our own experience some patients with R/M HNSCC who progressed very rapidly on immunotherapy, preventing us to safely continue the treatment.
We hypothesized that some HNSCC patients might experience an acceleration of tumor growth kinetics (TGK) on immunotherapy [14] . We therefore decided to test this hypothesis by retrospectively comparing TGK on immunotherapy and on last treatment in a cohort of R/M HNSCC patients treated with PD-1/PD-L1 inhibitors.
Patients and methods

Patient selection
Data from R/M HNSCC patients treated with PD-1/PD-L1 inhibitors in four French centers (Antoine Lacassagne Center, Nice; Léon Bérard Center, Lyon; Curie Institute, Paris; Gustave Roussy, Villejuif) between September 2012 and September 2015 were retrospectively collected. Patients had a histologically confirmed R/M HNSCC treated with anti-PD-1/PD-L1 therapy. All patients received the PD-1/PD-L1 inhibitors at the recommended phase II dose.
Patients had to have an available pre-baseline CT-scan in order to assess TGK before starting immunotherapy. All pre-baseline and on immunotherapy imaging were retrospectively reviewed in order to assess the ORR and the progression-free survival (PFS) according to RECIST 1.1 and irRECIST, as well as TGK before starting immunotherapy (TGK PRE ) and on immunotherapy (TGK POST ).
Following data were recorded: age at diagnosis, gender, primary tumor location, TNM stage at diagnosis, number of previous lines of systemic therapy, best overall response on immunotherapy, dates of pre-baseline imaging as well as on immunotherapy imaging, patterns of recurrence, location of distant metastases, HPV status, and largest diameter of target lesions.
All imaging were non-blindly reviewed by physicians who performed all tumor measurements from pre-baseline imaging to on immunotherapy imaging. For each patient, target lesions were reassessed using RECIST 1.1 [15] and irRECIST [12] .
Assessments
T PRE , T 0 , and T POST stand for the time of pre-baseline, baseline, and first imaging, respectively. S PRE , S 0 , S POST stand for the sum of the largest diameter of target lesions at pre-baseline, baseline, and first imaging, respectively.
TGK PRE was defined as the difference of the sum of the largest diameters of the target lesions (according to RECIST) per unit of time between pre-baseline and baseline imaging: (S 0 ÀS PRE )/(T 0 ÀT PRE ). Similarly, TGK POST was defined as (S POST ÀS 0 )/(T POST ÀT 0 ).
The TGK ratio (TGK R ) was defined as the ratio of TGK POST to TGK PRE . TGK R > 1 indicated tumor growth acceleration, while 0 < TGK R < 1 and TGK R < 0 indicated tumor deceleration and tumor shrinkage, respectively. Hyperprogression was defined as TGK R ! 2 ( Figure 1 ).
Statistical analyses
Statistical comparisons were performed using v 2 or Fisher's exact tests for categorical data and student's test or Mann-Whitney's test for continuous variables. Smoothing spline ANOVA model was used for evaluation of relation between the TGK PRE and the TGK POST [16] .
OS and PFS were estimated and presented graphically using the KaplanMeier method. Patients were censored at the time of death or last followup. Survival rates at various times and 95% confidence intervals were also estimated. The survival curves were compared using the log-rank test.
All statistical analyses were performed in 5% alpha risk or 95% confidence interval using R.3.2.2 software on WindowsV R , and gss R package for smoothing spline ANOVA model [16] .
Results
Patient characteristics
Among 64 identified R/M HNSCC patients treated with anti-PD-1/PD-L1 blockers, 34 patients were eligible. The remaining 30 patients were not included in the final analysis because of the absence of available pre-baseline imaging (13 patients), the absence of available post treatment imaging (12 patients), no variation in the sum of target lesions between pre-baseline imaging and baseline imaging (3 patients), and non-measurable disease on prebaseline imaging (2 patients).
Median age was 63 years (Table 1) . Primary tumor location was oral cavity, oropharynx, larynx, and hypopharynx in 11 (32%), 12 (35%), 5 (15%), and 6 (17%) patients, respectively. Patterns of recurrence included exclusive loco-regional recurrence in 14 patients (41%), exclusive distant metastases in 11 patients (33%), and both in 9 patients (26%). No delays, interruption, or discontinuation of the anti-PD1/PD-L1 agents have been registered for the 34 patients. During the pre-baseline period (pre-baseline to baseline point), 19 patients did not have a systemic treatment (median wash-out duration: 45 days, range 19-306 days) and 15 patients got a systemic treatment (median prebaseline period: 68 days, range 21-164 days) without any delay, interruption, or discontinuation.
Response to treatment
Median follow-up was 10.3 months (95% CI 5-1). Best overall response was complete response in 1 patient (3%), partial response in 3 patients (9%), stable disease in 13 patients (38%), and progressive disease in 17 patients (50%).
Median PFS according to RECIST was 2.5 months (95% CI 2.2-3.9), while median PFS according to irRECIST was 4.9 months (95% CI 2.8-6.3). Median OS was 8 months (95% CI 4.7-10.1). 
TGK assessment
The evolution of the sum of the largest diameter of target lesions are represented for patients with regional recurrence, local recurrence, distant metastatic recurrence, and exclusively distant metastases are depicted in Figure 2 . Hyperprogression was observed in 10 patients (29%), but in only one out of the 11 patients (9%) with exclusively distant metastases and in 9 out of the 23 patients (39%) with at least a loco-regional recurrence (Figure 3) .
No pseudo-progression was reported.
Predictors of hyperprogression
Hyperprogression was more frequent in case of metastatic cervical nodes at diagnosis (42% versus 26%), although it did not reach statistical significance. Hyperprogression did not correlate with tumor size at baseline, T stage, M stage at diagnosis or tumor burden at baseline (Table 1) . Hyperprogression occurred in 4/19 (21%) patients who did not receive a systemic treatment during the pre-baseline period and 6/15 (40%) patients who got systemic treatment during the pre-baseline period (P ¼ 0.2). Hyperprogression significantly correlated with the presence of a regional recurrence (90% versus 37%, P ¼ 0.008), but not with the presence of a local recurrence.
Prognostic value of hyperprogression
Hyperprogression was associated with a shorter PFS according to RECIST (2.5 versus 3.4 months, P ¼ 0.003) ( Figure 4A ), and irRECIST (2.9 versus 5.1 months, P ¼ 0.02) ( Figure 4B ). Hyperprogression was associated with shorter OS (6.1 versus 8.1 months, P ¼ 0.77), although it did not reach statistical significance ( Figure 4C ).
Discussion
In our series, 29% of patients with R/M HNSCC experienced hyperprogression as defined by a TGK R exceeding two during anti-PD-1/PD-L1 therapy. This phenomenon was observed in 39% of patients with at least a loco-regional recurrence, and in 9% of patients with exclusively distant metastases. The occurrence of hyperprogression correlated with shorter PFS. No pseudo-progression was reported. Similar results were recently reported in patients with various tumor types treated with PD-1/PD-L1 blockers [17] . The rate of hyperprogressors in this latter study was 9% but authors discuss why their methodology, despite a higher number of included patients, may have led to an underestimation of the incidence of the phenomenon. Hyperprogression also correlated with a poor prognosis in both reports.
Three main hypotheses can be made to explain the acceleration of tumor growth. First, PD-1/PD-L1 inhibitors may cause a major immune reaction in some cases. The most frequent occurrence of hyperprogression in patients with cervical node recurrence supports this hypothesis. Mutations or polymorphisms in genes that encode immune modifiers may also explain the variability in the occurrence of the hyperprogression phenomenon. Second, PD-1/PD-L1 inhibitors may promote in some cases tumor proliferation. Indeed, the immune system is known to play a dual role and may contribute to cancer development through direct (i.e. induction of DNA damage by the generation of free radicals) and indirect mechanisms (i.e. angiogenesis and tissue remodeling promotion by the production of growth factors and matrix metalloproteinases induced by inflammation) [ [18] [19] [20] [21] [22] . Tumor proliferation may also be promoted by regulatory T cells that suppress antitumor T-cell responses. In this setting, the effect of PD-1 and PD-L1 inhibitors on innate immune cells is unknown. Third, previous irradiation might play a role since almost all cases of hyperprogression occurred in patients who had at least a locoregional recurrence in an irradiated field. Mechanisms behind this hypothesis are unknown. Our study has several limitations. First, our study was retrospective without any control arm. It would have been interesting to perform a similar analysis in a cohort of patients treated in the same setting with other drugs than checkpoint inhibitors. In the absence of a control group, one cannot assess the causality of the hyperprogression to the checkpoint blockade and must evoke non immune related hypothesis but also tumor intrinsic or systemic features in this specific population. However, the hyperprogressions we report here are in line with some of the patients reported on the spider plot of the KEYNOTE-012 who seem to progress very rapidly [11] . While we cannot exclude that the phenomenon of hyperprogression also exist with non-immunotherapeutic agents, the hyperprogressions we describe here in 29% of patients is clinically significant and warrants further exploration. The threshold of 2 for TGK R , that we use to define hyperprogression, is very high, since a doubling in size in one dimension means Â8 in volume. However, the methodology of a case-control retrospective study would not be unbiased. Interestingly, in the pivotal randomized trial CheckMate 141 [10] , the OS curves are superimposed during the first 3 months of treatment and then separate significantly. The PFS curves tend to favor the chemotherapy arm during a similar period, until they separate, suggesting that a subset of patients in the nivolumab arm progressed or died earlier than expected. A cost effective way to firmly define the phenomenon of hyperprogression would be the calculation of the TGK R in both the nivolumab and chemotherapy arms of the CheckMate 141 patients. Second, we used the RECIST criteria. The selection of target lesions may not reflect perfectly the evolution of the whole tumor burden. It remains to be determined whether the assessment of response and therefore PFS according to RECIST is a good surrogate for OS, as demonstrated with chemotherapeutic agents. Third, the small size of our series and the multiple tests performed objectively weaken the consistency of some results. Finally, we hypothesized that TGK would be stable over time without treatment, which might not hold true [23] . However, by comparing pretreatment and on treatment TGK, the TGK R better considers the natural history of the disease and mitigate the impact of inter-tumor TGK disparity. Because of all these limitations, our study is only hypothesis-generating and does not allow to firmly attribute the causality of hyperprogression to checkpoint blockade or conclude that hyperprogression significantly affected OS. Our results highlight the necessity to identify predictors of hyperprogression, in order not to treat these patients who might be harmed by immune check point inhibitors. At least, continuing immunotherapy beyond progression should be avoided except in carefully selected patients who really experience a clear clinical improvement during immunotherapy. Biopsies at the time of progression would clearly help understanding the biological mechanisms of hyperprogression.
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